Actualités Connect Biopharma Holdings Inc - CNTB | Actions NASDAQ

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED...

Statement of Ownership (sc 13g)

Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Connect Biopharma Provides Business and Clinical Development Program Update

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program...

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited...

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited...

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with...

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,tomorrow, Tuesday, October 4 SAN...

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic...

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Connect Biopharma Holdings Inc (CNTB)

Outils de qualité professionnelle, pour des investisseurs individuels.

CNTB Actualités

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Statement of Ownership (sc 13g)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Provides Business and Clinical Development Program Update

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Connect Biopharma Holdings Inc (CNTB) Actualités

Connect Biopharma Holdings Inc (CNTB)

Outils de qualité professionnelle, pour des investisseurs individuels.

CNTB Actualités

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Statement of Ownership (sc 13g)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Provides Business and Clinical Development Program Update

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application